Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Porcine Epidemic Diarrhea Vaccines Market, and What Factors Will Drive It?
The market for vaccines for porcine epidemic diarrhea has experienced significant expansion in the recent past. The market is projected to increase from $1.67 billion in 2024 to $1.8 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%. The growth observed during the historic period can be credited to major vaccination drives, extended immunization programs (EPI), the use of disposable syringes, initiatives to wipe out diarrhea, and strategies such as the global alliance for vaccines and immunization (GAVI).
There is an anticipated robust expansion in the porcine epidemic diarrhea vaccines market in the upcoming years, with a projected value of $2.37 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.1%. The acceleration in the predicted period can be ascribed to the escalating emphasis on vaccination initiatives, wider vaccine development schemes, increasing pig counts, concentration on cold chain administration, and growing consciousness about the necessity of preventive health measures. The significant trends expected in this period encompass ongoing innovation in vaccine delivery instrument technology, a shift towards needle-free alternatives, advancements in personalized healthcare, a rising inclination towards vaccines administered independently, and the fortifying of animal health infrastructure and distribution networks.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16514&type=smp
Which Primay Drivers Are Accelerating Growth in the Porcine Epidemic Diarrhea Vaccines Market?
The expansion of pig farming is projected to fuel the porcine epidemic diarrhea vaccine market’s growth. This type of farming involves the breeding, rearing, and management of domestic pigs from birth to market weight for meat production, in addition to the marketing and sale of pork products. The growth in pig farming can be attributed to the escalating global interest in pork products, advancements in breeding and management strategies, tech-driven improvements in farming methods, and widening markets for pork consumption. To prevent and control PED outbreaks, porcine epidemic diarrhea vaccines are used in pig farming, typically either through injection or orally starting from the sow’s gestation period. This protects newborn piglets by transferring passive immunity through colostrum. The United States Department of Agriculture, a US government department, has reported that pork production in the United States saw a 1 percent increase over the previous year, reaching 40.6 billion pounds in 2022. As such, the growth of the porcine epidemic diarrhea vaccine market is being driven by the expanding pig farming industry.
Which Primary Segments of the Porcine Epidemic Diarrhea Vaccines Market Are Driving Growth and Industry Transformations?
The porcine epidemic diarrhea vaccines market covered in this report is segmented –
1) By Product: Live Vaccines, Killed Vaccines
2) By Application: Piglets, Adults Pigs
3) By End-User: Veterinary Hospitals, Hog Production Farms
Subsegments:
1) By Live Vaccines: Oral Live Vaccines, Injectable Live Vaccines
2) By Killed Vaccines: Inactivated Injectable Vaccines, Inactivated Oral Vaccines
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16514&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Porcine Epidemic Diarrhea Vaccines Market?# Market?
Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2024. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Porcine Epidemic Diarrhea Vaccines Industry Dynamics?
Leading firms in the market for porcine epidemic diarrhea vaccines are introducing novel products like the porcine parvovirus (PPV) vaccine to bolster their market presence. The PPV vaccine, designed for animal use, aims to prevent reproduction failures in pigs due to the PPV, a tiny, non-enveloped virus linked to infertility, mummified foetuses, stillbirths, and debilitated piglets. For example, in March 2022, the German pharmaceutical company Boehringer Ingelheim unveiled the ReproCyc ParvoFLEX porcine parvovirus (PPV) vaccine. Designed innovatively to fight reproduction failures in pigs, this vaccine, attributed to a small, non-enveloped virus, is aimed at addressing issues like infertility, mummified foetuses, stillbirths, and weak piglets. The distinction of this vaccine launch is the sophisticated formulation and effectiveness, providing full-scale defense against PPV-induced reproductive failures, thus protecting the health and productivity of pig populations.
View the full report here:
What Parameters Are Used to Define the Porcine Epidemic Diarrhea Vaccines Market?
Porcine epidemic diarrhea (PED) vaccines are biological preparations developed to provide immunity against the porcine epidemic diarrhea virus (PEDV), which causes severe gastrointestinal disease in pigs. These vaccines are essential tools in preventing and controlling Porcine Epidemic Diarrhea, contributing to the health and productivity of pig populations and the economic stability of the swine industry.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16514
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model